Trellis Bioscience, a South San Francisco company that monitors cells at the individual level to assess what sort of treatments to give people, said it has raised $10 million in a second round of financing.

Novartis Bioventures led the round, which included Pac-Link Bio Venture Investment Corporation and Sagamore Bioventures. Previous investors also participated, including Easton-Hunt Capital Partners and Morgenthaler Partners.

Trellis additionally announced that Markus Goebel, M.D., Ph.D., managing director of Novartis Bioventures, will join the Trellis Board of Directors.

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Learn more about membership.